and probucol, which act as radical scavenging antioxidants, were developed as anti-atherosclerotic medicines.
Introduction
It has been suggested that the oxidative modification of low density lipoprotein (LDL) is a key initial event in the pathogenesis of atherosclerosis (1). As a consequence, the role of antioxidants, which protect LDL from oxidative modification, has received considerable attention and both natural and synthetic antioxidants have been studied for their anti-atherogenic potency. Epidemiological studies and supplementation data suggest that a high intake of vitamin E is in general able to reduce the risk of coronary heart disease (2).
Based on the chemical structure of a-tocopherol, a novel antioxidant 2, 3-dihydro-5-hydroxy-2, 2-dipentyl-4, 6-di-tert-butylbenzofuran (BO-653) was designed and synthesized.
It was found that BO-653 exerted a potent antioxidant activity against lipid peroxidation (3) and oxidative modification of LDL (4, 5) and also exhibited anti-atherogenic effects in three different animal models (6). Probucol, 4, 4'-isopropylidenedithio-bis-(2, 6-ditert-butyiphenol), is a drug used in the treatment of hypercholesterolemia, but is also capable of acting as an antioxidant (7). It has been observed that probucol prevents the development of atherosclerotic lesions in Watanabe heritable hyperlipidemic (WHHL) rabbits, an animal model of familial hypercholesterolemia (8) (9) (10) (11) (12) (13) (14) . Furthermore, recent studies have shown probucol to be effective in reducing the incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA) (15) (16) (17) (18) , and the drug has received renewed attention. However, it has also been observed that probucol exacer- Takabe et al. bates the development of atherosclerosis in certain animal models (6, (19) (20) (21) . It is difficult to explain these discrepancies in the anti-atherogenic effects of antioxidants in terms of their radical scavenging activity against oxidative modifications of LDL.
In 1978, Benson et al. (22) and Cha et al. (23) first presented evidence that dietary administration of antioxidants induced phase II xenobiotic metabolizing enzymes. These results suggested that antioxidants not only directly inhibit free radical-mediated reactions, but also to increase the activity of enzymes which readily metabolize cytotoxic chemicals. Transcriptional activation by antioxidants has been demonstrated to be the result of enhanced transcription factor binding to a cis-acting element, known as the antioxidant responsive element (ARE) (24) or the electrophile responsive element (EpRE) (25), which is associated with target genes. It is assumed that antioxidant itself and/or antioxidant-derived radical affect the redox state of transcription factors. Recently, reports have shown that a -tocopherol but not fl-tocopherol negatively regulates proliferation of vascular smooth muscle cells by preventing PKC activation (26, 27) . Inhibitory effects of a -tocopherol on the expression of adhesion molecules in HUVEC and leukocytes have also been reported (28).
The regulation of gene expression by anti-atherogenic antioxidants remains a subject of great interest. In the present study, we investigated gene expression induced by BO-653, probucol and BHQ in HUVECs by means of DNA chip technology.
Methods

Antioxidants
2, 3-Dihydro-5-hydroxy-2, 2-dipentyl-4, 6-di-tertbutylbenzofuran (BO-653) was a kind gift from the Chugai Pharmaceutical Co. 4, 4'-isopropylidenedithio-bis-(2, 6-di-tert-butylphenol) (Probucol) was kindly supplied by the Daiichi Pharmaceutical
Co. tert-Butylated hydroquinone (BHQ) was purchased from SIGMA.
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were obtained from a commercial source (Clontics Corp, CA) and grown in Endothelial Cell Growth Factor Containing Medium-2 (EGM-2, Clontics Corp, CA) with 2% fetal bovine serum (FBS) at 37°C in a 5% CO2 atmosphere. All experiments were done in 4 passages.
After reaching confluency, cells were deprived of growth factors for 2 hr before the addition of antioxidants.
The final concentration of BO-653 and probucol were 50 ,u M and that of BHQ was 0.5 ,u M. Antioxidants were dissolved in dimethylsulfoxide (DMSO, SIGMA, St. Louis, MO Tissue distribution of KIAA0018 and KIAA0064 mRNA Tissue distribution of KIAA0018 and KIAA0064 mRNA was studied using a RAPID SCAN GENE EXPRESSION PANEL (OriGene, MD), which contains first-stand cDNA from 23 human tissues arrayed in a 4-log dilution enabling amplification and visualization within the linear range of PCR (34).
Results
Expression profile of genes induced by antioxidants Table 1 shows the genes inducible in HUVECs by the addition of BO-653, probucol and BHQ. Among the 6,416 genes on the chip, 17 genes were induced by each of the antioxidants applied in this experiment more than three fold. Two unidentified genes, which were named KIAA0018 and KIAA0064, were found to be the most strongly induced by the three antioxidants.
The descriptive information is summarized in Table 2 . Most of the other genes induced by the three antioxidants were classified as cell-cycle and mitochondrial function related genes. To illustrate the specificity for each antioxidant, genes that were induced by only one or two antioxidants of the three tested are listed in Table 3 . There were 5 genes that were induced by BO-653 and BHQ, of which 4 were found to be mitochondria-related. The expression of a gene for cytochrome P-450 1A1 isozyme, one of the important drug-metabolizing phase I enzymes, was induced only by BHQ. Except for the cytochrome P-450 1A1 gene, BO-653 and BHQ exhibited similar patterns of gene expression induction in HUVECs.
Reduction of gene expression by antioxidants
As shown in Table 4 , several genes were found to be reduced in expression by BO-653, probucol and BHQ. The expression of genes encoding three proteasome subunits, i.e., PSMA3, PSMA4 and PSMA2 was predominantly reduced by these antioxidants.
Proteasomes are protein complexes, which distribute ubiquitously and degrade unnecessary proteins. The human FL Gene Chip contains 19 other proteasome-related genes. Some of these genes were recluced by although the statistic calculation was not significant and others were not attectecl by these antioxiclants.
According to the downregulation profile summarized in Table 5 , genes encoding proteins related to protein metabolism were affected by these antioxidants.
Tissue distribution of KIAA0018 and KIAA0064 mRNA in human organs and cells
The relative expression levels of the KIAA0018 and KIAA0064 genes in human organs were studied using a set of cDNA obtained from 23 human organs and cell types, standardized to contain the same amount of betaactin cDNA. As shown in Fig. 2a, KIAA0018 mRNA was exclusively expressed in lung and pancreas.
On the Takabe  et al. other hand, KIAA0064 mRNA was most highly expressed in the pancreas, followed by the adrenal gland, thyroid gland, salivary gland, skin, heart, liver, lung, small intestine, skeletal muscle, placenta and colon (Fig. 2b ).
Discussion
In this study, we investigated the effects of anti-atherogenic antioxidants on gene transcription in HUVEC by means of a DNA chip. Out of the 6,416 genes on the oligonucleotide chip, two KIAA clones were potently induced by all three antioxidants studied.
Originally, the coding sequences of the KIAA0018 and KIAA0064 genes were determined by Nomura et al. (35, 36) , but their functions remain unelucidated.
Therefore, in the present study, we investigated tissue distribution of these genes as an initial attempt.
We submitted the amino acid sequences of these two clones to several structure and function predicting software packages.
Using a software named SOSUI (http://azusa.proteome.bio .tuat.ac.jp/ sosui/), which can estimate hydrophobicity, and predicts the association with lipid bilayers, we deduced that KIAA0018 protein is a membrane protein with 2 transmembrane domains, and KIAA0064 is a soluble protein. By using another software package, BLAST Search (http:// www.ncbi.nlm.nih.gov/BLAST/), it was predicted that KIAA0018 and KIAA0064 contained the consensus domain for FAD-binding and the Eph-like receptor, respectively.
Cytochrome P-450s consist of a superfamily of hemecontaining enzymes which hydroxylate a variety of organic substrates by utilizing molecular oxygen (37). Cytochrome P-450 1A1 isozyme is one of the drugmetabolizing phase I enzymes and is strongly induced by dioxin and aryl hydrocarbon.
Although the activity of P-450 isozyme as a phase I enzyme is important in the metabolism of toxic compounds, its overexpression often causes the formation of electrophilic intermediates able to covalently modify DNA, proteins and lipids, resulting in carcinogenesis (38). In this study, cytochrome P-450 1A1 was induced only by BHQ, which has been identified as a toxic compound.
On the other hand, BO-653 and probucol did not induce cytochrome P-450 1A1 even at 100 times higher concentrations than BHQ, suggesting that treatment with the anti-atherogenic antioxidants employed in this experiment was not toxic to HUVEC.
BHQ has been reported to induce several drugmetabolizing phase II genes, which have the ARE in their promoter region (39). The expression levels of phase II enzymes such as glutathione-s-transferases and NADPH quinone oxidoreductase can be analyzed with HuFL gene chips, but none was found to be affected by the addition of BHQ in this experiment. This may be primarily due to the different cell types utilized in the earlier reports. This is the first report of gene expression induced by phenolic antioxidants in HUVEC. Secondly, these genes may react earlier or later than at the 6 hour treatment time point with antioxidants used in this study. Finally, the concentration of antioxidants that we have used in this study may not be sufficient to induce phase II enzymes.
As indicated in Table 1 , the absolute fold changes induced by probucol were smaller than those induced by BO-653 and BHQ, suggesting that probucol exhibited less effect on gene transcription. This may be due to differences in the intracellular concentrations of the antioxidants, which are determined by the rate of incorporation into cells. In fact, a kinetic study showed that the rate of incorporation of probucol was about half that of BO-653 (data not shown).
However, it was noticed that the absolute fold change calculated by the Genechip Software did not always reflect change in expression of the gene. Confirmation by other analytical methods such as Northern blotting should be performed.
The ubiquitin-proteasome pathway degrades the inhibitory binding protein, 1-kB, that ordinarily sequesters nuclear factor kB (NF-kB) in the cytoplasm.
The degradation of 1-kB by proteasomes allows nuclear translocation of NF-kB. Inhibition of 1-kB degradation by a proteasome inhibitor blocks NF-kB activation.
Accordingly, the expression of the endothelial cell adhesion molecules (ECAMs) such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and E-selectin induced by tumor necrosis factor (TNF)-alpha was suppressed (40, 41). It has been accepted that these adhesion molecules play important roles in the development of atherosclerotic lesions.
From the present study, it is suggested that BO-653 and probucol might act as anti-atherogenic antioxidants by inhibiting expression of ECAMs via a reduction of proteasome activity.
It is also reported (42) that the transcriptional activity of hypoxia inducible factor 1 (HIF-1) is regulated by a proteasome degradation process.
Several genes that are transactivated by HIF-1 have been identified, including those encoding erythropoietin, glycolytic enzymes, glucose transporters, and vascular endothelial growth factor (43, 44). The present results imply the possibility that antioxidant treatment may mimic the effects of hypoxia in the cell.
HUVECs are primary cultured endothelial cells from the human umbilical vein. The effects of anti-atherogenic antioxidants on endothelial cells of the aorta and coronary artery and other vascular cells such as smooth muscle cells are now under investigation.
Furthermore, comparative studies on antioxidant-inducible genes in cells from different species may enable us to understand discrepancies in anti-atherogenic effects of antioxidants observed in different animal models. 
